Kyoto Pharmaceutical Industries, Ltd.

Sankyo Company, Limited

Screen Holdings Co., Ltd.

Shohei Nakamura

Hiroaki Shirahase

Hiroshi Matsui

Shoji Kamiya

Katsuo Wada

Motohiro Kono

Akihisa Yoshimi

Shigeru Takatsuji

Akira Horikoshi

Mamoru Kanda

Kenji Kobayashi

Fumio Fukata

Takahiro Kimura

A liquid film of a processing liquid containing at least one of sulfuric acid, a sulfate, peroxosulfuric acid, and a peroxosulfate, or a processing liquid containing hydrogen peroxide is formed on a substrate. A plasma is radiated to the liquid film. Thereby, a substrate processing method in which substrate processing using an oxidizing power of the processing liquid can be efficiently performed is provided.

Substrate processing method and substrate processing apparatus

An in-liquid plasma generation device includes a housing which holds a liquid in an internal space, a gas supply tube which includes an opening in the internal space and discharges a gas into the liquid through the opening, a first electrode which has projecting part projecting into the internal space via the opening from inside of the gas supply tube, the projecting part including a conductor covered by a dielectric, a second electrode which surrounds the projecting part of the first electrode and includes a conductor isolated from the liquid by a dielectric, and a voltage applier which applies a voltage to between the first electrode and the second electrode. A space between the projecting part and the second electrode is a flow passage in which the gas discharged from the opening flows.

In-liquid plasma generation device and liquid treatment apparatus

A heterocyclic derivative of the formula (I)wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors

Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof

The cromoglycic acid compound of the formula (I)

Medicinal use of cromoglycic acid compounds

A heterocyclic derivative of the formula (I)

Heterocyclic derivatives and pharmaceutical use thereof

A therapeutic agent for allergic dermatitis caused by type IV allergic reaction, which contains diethyl L-lysylcromoglycate of the formula:

Therapeutic agent for allergic dermatitis

Heterocyclic derivatives of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and method of producing them. Pharmaceutical compositions containing the heterocyclic derivative or a pharmaceutically acceptable salt thereof, particularly, ACAT inhibitors and lipoperoxidation inhibitors. The heterocyclic derivatives and pharmaceutically acceptable salts thereof of the present invention show superior ACAT inhibitory activity and lipoperoxidation inhibitory activity, and are useful as ACAT inhibitors and hyperlipemia inhibitors. To be specific, they are useful for the prevention and treatment of arteriosclerotic lesions of arteriosclerosis, hyperlipemia and diabetes, as well as ischemic diseases of brain, heart and the like.

Method for inhibiting acyl-CoA : cholesterol acyltransferase

Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or

Heterocyclic derivatives, method of production thereof and

An imidazole derivative of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof is described. A method for producing the compound or its salt, and its pharmaceutical use, particularly as an agent for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine are described. Also, compounds of the formula (II) and (IV) ##STR2## wherein each symbol is as defined in the specification are described. The imidazole derivative and its parmacologically acceptable salt are useful as agents for the prophylaxis and treatment of the diseases induced by thromboxane A.sub.2 or histamine, and the intermediate compounds (II) and (IV) are novel compounds.

Growing community of inventors

Kyoto, Japan

Shohei Nakamura